产品名称：Losatuxizumab
产品别称：ABT-806, PR-1316749
靶点：EGFR[Homo sapiens]
抗体亚型：IgG1
来源：CHO cells
体内实验：在异种移植小鼠模型中，Losatuxizumab对高表达WT EGFR的鳞状细胞癌有显著的生长抑制效果[1]。
| Animal Model | squamous cell carcinoma xenograft models |
| Dosage | 10,40 mg/kg |
| Result | Inhibits the growth of squamous cell carcinoma xenograft models expressing high levels of wild-type EGFR. |
在人源性组织异体移植模型中，Losatuxizumab能够显著抑制多形性胶质母细胞瘤生长，延长小鼠生存期[1]。
| Animal Model | glioblastoma multiforme patient-derived xenograft |
| Dosage | 40 mg/kg |
| Result | Prolonged survival rate, and reduced levels of pEGFR in tumor. |
参考文献：Reilly EB, Phillips AC, Buchanan FG, et al. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther. 2015;14(5):1141-1151. doi:10.1158/1535-7163.MCT-14-0820
仅供科研使用
